ストックスクリーナーアプリを入手
27.47
0.62%
-0.17
プレマーケット:
27.19
-0.28
-1.02%
前日終値:
$27.64
開ける：
$27.64
24時間の取引高:
6.08M
Relative Volume:
0.57
時価総額：
$10.62B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-3.1466
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
-15.89%
1か月 パフォーマンス:
-9.90%
6か月 パフォーマンス:
-21.47%
1年 パフォーマンス:
-67.20%
1日の値動き範囲:
$27.30
$27.97
1週間の範囲:
$26.56
$33.40
52週間の値動き範囲:
$23.15
$91.99
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
27.47 | 10.75B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
RFK Jr. Axes 22 mRNA Vaccine Projects Under BARDA - BioSpace
ABC Arbitrage SA Takes Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
HHS halts funding for mRNA vaccine activities (MRNA:NASDAQ) - Seeking Alpha
RFK Jr. Halts $500 Million In mRNA Vaccine Projects Backed By Pfizer, Moderna: 'We're Prioritizing Safer, Broader Strategies' - Benzinga
Moderna Stock: Is Wall Street Bullish Or Bearish? - Barchart.com
Envestnet Asset Management Inc. Sells 12,212 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Wealthquest Corp Buys Shares of 36,587 Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca - Stocktwits
US Health Department Pulls Back on Funding mRNA Vaccine Research - Bloomberg.com
US health agency to wind down mRNA vaccine development - Reuters
14,589 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Banque Cantonale Vaudoise - MarketBeat
Barclays Has Lowered Expectations for Moderna (NASDAQ:MRNA) Stock Price - MarketBeat
Moderna: RSV Upside Slim, Cash Burn Heavy (NASDAQ:MRNA) - Seeking Alpha
Let’s make a deal? Big Pharma execs express varying views on their M&A future - PharmaVoice
Lipid Nanoparticles Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034 - GlobeNewswire Inc.
Zurcher Kantonalbank Zurich Cantonalbank Sells 134,443 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Holdings Cut by Pacer Advisors Inc. - MarketBeat
Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1 - The Florida Times-Union
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Pocono Record
Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Courier-Journal
Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case - Law360
BofA Securities lowers Moderna stock price target to $24 on COVID reliance - Investing.com
EU regulator backs Moderna's updated COVID vaccine - MSN
Moderna Tops Vaccine Expectations But Trims Future Outlook - Finimize
Moderna stock falls as UBS reiterates Buy rating amid cost cuts - Investing.com Canada
How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com
Moderna Q2 Earnings Review: Downsizing Triggers Selloff, But I'm Long-Term Bullish (MRNA) - Seeking Alpha
Moderna (NASDAQ:MRNA) Announces Quarterly Earnings Results - MarketBeat
OVERSEA CHINESE BANKING Corp Ltd Has $1.16 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
XTX Topco Ltd Raises Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What is Moderna Inc. company’s growth strategyPowerful profit generation - Jammu Links News
Private Advisor Group LLC Sells 13,174 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
What analysts say about Moderna Inc. stockMaximize your portfolio’s growth potential - jammulinksnews.com
Moderna: Is Now the Time to Buy the Deep Value Dip? - FXEmpire
Moderna’s Hold Rating: Navigating Revenue Adjustments and Product Development Uncertainties - TipRanks
What are Moderna Inc. company’s key revenue driversHigh-octane gains - jammulinksnews.com
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio? - Benzinga
When is Moderna Inc. stock expected to show significant growthHigh-octane financial growth - Jammu Links News
Is Moderna Inc. a growth stock or a value stockBuild wealth faster with expert stock selection - Jammu Links News
What institutional investors are buying Moderna Inc. stockUnrivaled growth potential - Jammu Links News
Letko Brosseau & Associates Inc. Has $25.41 Million Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Sees Unusually High Options Volume (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Shares Gap DownTime to Sell? - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Q2 2025 Earnings Call Transcript - Insider Monkey
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Federated Hermes Inc. - MarketBeat
Moderna Inc (MRNA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost ... - Yahoo Finance
Moderna Inc (MRNA) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Cost Reductions and New Approvals - GuruFocus
Moderna’s Q2 2025 Financial Results and Outlook - TipRanks
Moderna Outpaces Losses With Cost Cuts And New Plans - Finimize
Moderna's Q2 Earnings and Strategic Cost Cuts: A Path to Sustainable Recovery? - AInvest
Moderna: Q2 Earnings Snapshot - Norwalk Hour
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.40%
0.08%
大文字化:
|
ボリューム (24 時間):